Sign inJoin waitlistJoin the waitlist

Kim Margolin

Medical Director of the Saint John's Cancer Institute Melanoma Program · Saint John's Cancer Institute

Credentials: · · · · · · ·

History

Saint John's Cancer Institute Melanoma Program Center
Present
Melanoma Program · Saint John's Cancer Institute
Present

Hematology and Medical Oncology
Yale-New Haven Hospital
1982–1985
Yale-New Haven Hospital
1979–1982
Stanford University School of Medicine
1975–1979

Research

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Journal of Clinical Oncology · 2015 · 1,681 citations
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
Journal of Clinical Oncology · 1999 · 1,620 citations
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,307 citations

James Doroshow
83 papers
LL
Lucille Leong
64 papers
GS
George Somlo
63 papers
Michael Atkins
48 papers
Jeffrey Sosman
34 papers
SS
Stephen Shibata
34 papers
Steven Akman
34 papers
Warren Chow
33 papers
GW
Geoffrey Weiss
30 papers
Stephen Forman
28 papers
RM
Robert Morgan
25 papers
YY
Yun Yen
25 papers

Grants

City of Hope Southwest Oncology Group Clinical Trials
National Cancer Institute · U10
Contact PI · $1.1M · Beckman Research Institute/City of Hope
1988–2009
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $168.1K · University of Southern California
2003–2007

Clinical trials

Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
Principal investigator · Unknown · Phase 2
ImaginAb, Inc.
2021–2025
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2010–2015
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2007–2011
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Principal investigator · Completed · Phase 2
Beth Israel Deaconess Medical Center
2006–2013